Login to Your Account

Alkermes Left at the Altar as Lilly Kills AIR Program

By Donna Young

Monday, March 10, 2008
Shares of Alkermes Inc. dropped 9.2 percent Friday after the firm confirmed rumors in the market that its partner Eli Lilly and Co. plans to pull out of its deal to develop and commercialize AIR Inhaled Insulin, which currently is in Phase III development for diabetes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription